Physician profile
John Lott
NPI 1710691423
$655.17
in general payments reported to CMS, 2019-2025
13 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $389 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.86 | 2024-2025 | |
| Novo Nordisk INC | $102.39 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Neurocrine Biosciences, INC. | $67.06 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.29 | 2024-2025 | Caplyta |
| Alkermes, INC. | $51.47 | 2024 | Vivitrol |
| Merck Sharp & Dohme LLC | $37.24 | 2024-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Axsome Therapeutics, INC. | $27.04 | 2024 | Auvelity |
| Medtronic, INC. | $21.57 | 2025 | Reveal Linq |
| Glaxosmithkline, LLC. | $19.32 | 2025 | Trelegy Ellipta |
| Scpharmaceuticals INC. | $18.66 | 2024 | |
| Exact Sciences Corporation | $16.29 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $13.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.48 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.